NCT01124864 - A Study of AUY922 in Non-small-cell Lung Cancer Patients Who Have Received Previous Two Lines of Chemotherapy. | Biotech Hunter

Enrollment

153

Participants

Timeline

Start Date

October 31, 2010

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions

Non-small-cell Lung Cancer

Interventions

DRUG

AUY922

AUY922 was supplied in individual 10 mL amber colored glass ampoules containing 10 mL of a 5 mg/mL active drug substance in 5% aqueous glucose solution. AUY922 was administered intravenously (i.v.) weekly at 70 mg/m2.

Trial Locations (22)

13125

Novartis Investigative Site, Berlin

13915

Novartis Investigative Site, Marseille

20850

Maryland Oncology Hematology, P.A. Dept. of Assoc. Onc/Hem, Rockville

26121

Novartis Investigative Site, Oldenburg

35040

Novartis Investigative Site, Izmir

90095

University of California at Los Angeles UCLA - Santa Monica, Los Angeles

94000

Novartis Investigative Site, Créteil

94805

Novartis Investigative Site, Villejuif

119228

Novartis Investigative Site, Singapore

02215

Dana Farber Cancer Institute DFCI, Boston

Unknown

St. Luke's Hospital and Health Network St Luke's, Bethlehem

T6G 1Z2

Novartis Investigative Site, Edmonton

H3T 1E2

Novartis Investigative Site, Montreal

1081 HV

Novartis Investigative Site, Amsterdam

9713 GZ

Novartis Investigative Site, Groningen

NO-0379

Novartis Investigative Site, Oslo

05505

Novartis Investigative Site, Seoul

06351

Novartis Investigative Site, Seoul

110 744

Novartis Investigative Site, Seoul

137-701

Novartis Investigative Site, Seoul

08916

Novartis Investigative Site, Badalona

08035

Novartis Investigative Site, Barcelona